Ocular Hypotensive Efficacy of AR-102

Completed · Phase 2

Conditions studied: Glaucoma

In brief

A double-masked, randomized, vehicle-controlled, dose-response study assessing the safety and ocular hypotensive efficacy of AR-102 in subjects with elevated intraocular pressure. The Null hypothesis is that the ocular hypotensive efficacy of each dose of AR-102 Ophthalmic Solution will not be different from that of its vehicle.

Key facts

Study ID
NCT00523250
Run by
Aerie Pharmaceuticals
People needed
82
Starts
2007-09-01
Expected to finish
2008-03-01
Last updated by the study team
2014-05-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.